Here we summarize the recent literature concerning the potential mechanisms of IL-17A that is involved in the comorbidity of psoriasis and atherosclerosis, thus providing a theoretical basis for IL-17A inhibitors treating patients with psoriasis and comorbid atherosclerotic disorders. This evidence concerns the gene IL17A and atherosclerosis.